Long Acting Opioids Aren’t: And Other Lessons Learned About Chronic Pain Management | Andrea Rubenstein, MD
This presentation is part of the 2020 State of the Art in Addiction Medicine conference which covers an expansion of treatment into correctional health, hospital consultation services and emergency rooms. It will cover how, despite the pandemic, telehealth can reach those who are isolated. It will address the worrisome trends in fentanyl, methamphetamine, tobacco and benzodiazepines use; legalization of cannabis, treatment updates for youth, cannabis and alcohol in pregnant women; and novel treatments such as non-benzodiazepines for alcohol withdrawal and psychedelics for substance use disorders.
Learners cannot sign up for individual lectures, only for the full 2020 State of the Art in Addiction Medicine. Please contact CSAM (email@example.com) if you have any questions about this online educational offering.
Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care, psychiatry and other specialty field clinicians who want a better understanding of addiction and to improve their care of patients with unhealthy substance use
- Public policy makers, administrators and advocates who want an understanding of the current state of the field of addiction and its grater implications including towards prevention, access to care, integrated systems of care and healthcare technology
- Other healthcare professionals, including psychologists, therapists, nurses, and addiction counselors, who are involved in the treatment of patients with or at risk of substance use
- At the end of this discussion participants should have a deeper understanding of problems associated with extended release opioids (CR, SR, ER) and how the use of these drugs has “fed” the opioid crisis.
- particpants should gain a deeper understanding of the pharmacokinetics of long-acting opioid preparations and why they often "dont last"
- Participants should come away with a deeper understanding of both safety and efficacy issues related to long-acting opioid preparations.
Andrea L. Rubinstein, MD
Dr. Rubinstein is an anesthesiologist who specializes in chronic pain. Prior to medical school, she worked as a software engineer and has a special love for 'solving difficult problems' and she uses an individualized problem solving approach in all her clinical work. Dr. Rubinstein attended Stanford University Medical School and completed her residency in anesthesiology at Duke University. While at Stanford, she became fascinated with pain, and acutely aware of medicines limitations when it comes to solving many of the problems associated with pain.
She joined Kaiser Permanente in 2007, where she serves as chief of the department of pain medicine in Santa Rosa, California. . She sees her role as one of helping patients find creative solutions to difficult pain syndromes. To do this work, she uses a multi-disciplinary, bio-psycho-social approach, optimizing physical reconditioning and therapy, medications, blocks and injections.
Dr. Rubinstein divides her time between clinical work, research in the area of opioid risk and teaching and speaking about opioid pharmacology and novel ways to approach thinking about and treating pain
DISCLOSURE: No relevant financial relationships to disclose
The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.
(see additional information on page for parent course)
- 0.75 AMA Category 1
- 0.75 Attendance